These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 21762505)

  • 1. Modeling the effector - regulatory T cell cross-regulation reveals the intrinsic character of relapses in Multiple Sclerosis.
    Vélez de Mendizábal N; Carneiro J; Solé RV; Goñi J; Bragard J; Martinez-Forero I; Martinez-Pasamar S; Sepulcre J; Torrealdea J; Bagnato F; Garcia-Ojalvo J; Villoslada P
    BMC Syst Biol; 2011 Jul; 5():114. PubMed ID: 21762505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis.
    Gilmore W; Lund BT; Li P; Levy AM; Kelland EE; Akbari O; Groshen S; Cen SY; Pelletier D; Weiner LP; Javed A; Dunn JE; Traboulsee AL
    J Neuroinflammation; 2020 Jun; 17(1):189. PubMed ID: 32539719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autoantigen-specific immunosuppression with tolerogenic peripheral blood cells prevents relapses in a mouse model of relapsing-remitting multiple sclerosis.
    Kleist C; Mohr E; Gaikwad S; Dittmar L; Kuerten S; Platten M; Mier W; Schmitt M; Opelz G; Terness P
    J Transl Med; 2016 May; 14(1):99. PubMed ID: 27131971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Agent based modeling of Treg-Teff cross regulation in relapsing-remitting multiple sclerosis.
    Pennisi M; Rajput AM; Toldo L; Pappalardo F
    BMC Bioinformatics; 2013; 14 Suppl 16(Suppl 16):S9. PubMed ID: 24564794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thymic export function and T cell homeostasis in patients with relapsing remitting multiple sclerosis.
    Hug A; Korporal M; Schröder I; Haas J; Glatz K; Storch-Hagenlocher B; Wildemann B
    J Immunol; 2003 Jul; 171(1):432-7. PubMed ID: 12817027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The TCR Repertoire Reconstitution in Multiple Sclerosis: Comparing One-Shot and Continuous Immunosuppressive Therapies.
    Amoriello R; Greiff V; Aldinucci A; Bonechi E; Carnasciali A; Peruzzi B; Repice AM; Mariottini A; Saccardi R; Mazzanti B; Massacesi L; Ballerini C
    Front Immunol; 2020; 11():559. PubMed ID: 32328061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.
    Hersh CM; Cohen JA
    Immunotherapy; 2014; 6(3):249-59. PubMed ID: 24762071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vitamin D-mediated immune regulation in multiple sclerosis.
    Correale J; Ysrraelit MC; Gaitán MI
    J Neurol Sci; 2011 Dec; 311(1-2):23-31. PubMed ID: 21723567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monocyte and Lymphocyte Activation and Regulation in Multiple Sclerosis Patients. Therapy Effects.
    González-Oria MC; Márquez-Coello M; Girón-Ortega JA; Argente J; Moya M; Girón-González JA
    J Neuroimmune Pharmacol; 2019 Sep; 14(3):413-422. PubMed ID: 30649665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experimental models of relapsing-remitting multiple sclerosis: current concepts and perspective.
    Skundric DS
    Curr Neurovasc Res; 2005 Oct; 2(4):349-62. PubMed ID: 16181126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increase of CD8+ T-effector memory cells in peripheral blood of patients with relapsing-remitting multiple sclerosis compared to healthy controls.
    Haegele KF; Stueckle CA; Malin JP; Sindern E
    J Neuroimmunol; 2007 Feb; 183(1-2):168-74. PubMed ID: 17084910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal study of antimyelin T-cell reactivity in relapsing-remitting multiple sclerosis: association with clinical and MRI activity.
    Hellings N; Gelin G; Medaer R; Bruckers L; Palmers Y; Raus J; Stinissen P
    J Neuroimmunol; 2002 May; 126(1-2):143-60. PubMed ID: 12020966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of IL-16 in CD4+ T cell-mediated regulation of relapsing multiple sclerosis.
    Skundric DS; Cruikshank WW; Drulovic J
    J Neuroinflammation; 2015 Apr; 12():78. PubMed ID: 25896927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulatory effect of celastrol on Th1/Th2 cytokines profile, TLR2 and CD3+ T-lymphocyte expression in a relapsing-remitting model of multiple sclerosis in rats.
    Abdin AA; Hasby EA
    Eur J Pharmacol; 2014 Nov; 742():102-12. PubMed ID: 25218987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-27a and miR-214 exert opposite regulatory roles in Th17 differentiation via mediating different signaling pathways in peripheral blood CD4+ T lymphocytes of patients with relapsing-remitting multiple sclerosis.
    Ahmadian-Elmi M; Bidmeshki Pour A; Naghavian R; Ghaedi K; Tanhaei S; Izadi T; Nasr-Esfahani MH
    Immunogenetics; 2016 Jan; 68(1):43-54. PubMed ID: 26563334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Potential of Computational Modeling to Predict Disease Course and Treatment Response in Patients with Relapsing Multiple Sclerosis.
    Pappalardo F; Russo G; Pennisi M; Parasiliti Palumbo GA; Sgroi G; Motta S; Maimone D
    Cells; 2020 Mar; 9(3):. PubMed ID: 32121606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD8(+)Foxp3(+) T cells in peripheral blood of relapsing-remitting multiple sclerosis patients.
    Frisullo G; Nociti V; Iorio R; Plantone D; Patanella AK; Tonali PA; Batocchi AP
    Hum Immunol; 2010 May; 71(5):437-41. PubMed ID: 20138197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Computational modeling of the immune response in multiple sclerosis using epimod framework.
    Pernice S; Follia L; Maglione A; Pennisi M; Pappalardo F; Novelli F; Clerico M; Beccuti M; Cordero F; Rolla S
    BMC Bioinformatics; 2020 Dec; 21(Suppl 17):550. PubMed ID: 33308135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-independent B cell effector functions in relapsing remitting multiple sclerosis: clues to increased inflammatory and reduced regulatory B cell capacity.
    Ireland SJ; Blazek M; Harp CT; Greenberg B; Frohman EM; Davis LS; Monson NL
    Autoimmunity; 2012 Aug; 45(5):400-14. PubMed ID: 22432732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting relapsing-remitting dynamics in multiple sclerosis using discrete distribution models: a population approach.
    Velez de Mendizabal N; Hutmacher MM; Troconiz IF; Goñi J; Villoslada P; Bagnato F; Bies RR
    PLoS One; 2013; 8(9):e73361. PubMed ID: 24039924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.